Advanz Pharma to licence Dimerix’s DMX-200 drug candidate

Advanz Pharma has signed an agreement to licence Dimerix’s drug candidate DMX-200 for marketing in Australia, Canada, the European Economic Area, New Zealand, Switzerland and the UK.

Excluding these regions, Dimerix will retain complete commercialisation rights for DMX-200. 

The drug candidate is intended to treat focal segmental glomerulosclerosis (FSGS), a rare kidney ailment. It is currently evaluated in Phase III ACTION3 clinical trial in individuals with FSGS.

Dimerix will continue to finance and conduct the ACTION3 trial. 

Advanz will oversee the filing and regulatory dossier maintenance activities in the licenced regions, apart from handling the complete sales and marketing of the product. 

As per the deal, Dimerix is entitled to receive €6.5m ($6.81m) in upfront payment in 30 days in addition to milestone payments totalling up to €132m ($138.4m) on meeting development and commercialisation goals. 

Dimerix will also receive royalty payments on net product sales on the successful marketing of DMX-200.

The parties will also form a joint steering committee to oversee the development and commercialisation activities of DMX-200 for FSGS treatment in the territories. 

Advanz holds the right to negotiate a licence for the development and commercialisation of DMX-200 for further indications in its licenced territories.

Advanz CEO Steffen Wagner said: “We are excited to announce this partnership with Dimerix, which is fully in line with our strategy to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. 

“We are committed to bring innovative rare disease medicines to market which serve a high unmet patient need.”

In June 2023, the company entered into a partnership with Veeva Systems to establish a combined digital-first commercial foundation in Europe.